The FDA decision on Aadi Bioscience Inc.’s (AADI) Fyarro, proposed for the treatment of advanced malignant perivascular epithelioid cell tumor, is expected on November 26, 2021.Fyarro is a nanoparticle albumin-bound form of sirolimus in injectable suspension formulation. It is based on similar technology as Celgene’s chemotherapy drug Abraxane.Advanced perivascular epithelioid cell tumors, or advanced PEComas, are a rare subset of soft tissue sarcomas, for which there are no approved drugs. If approved, Fyarro will be the first FDA-approved therapy for the treatment of patients with this disease, according to Aadi.Fyarro has the potential to achieve peak sales of $2 billion by 2035, according to H.C. Wainwright & Co. analyst Robert Burns.AADI closed Thursday’s trading at $27.36, up 1.22%.